Prolyl hydroxylases 2 and 3 act in gliomas as protective negative feedback regulators of hypoxia-inducible factors.

Adaptive responses to hypoxia in tumors are transcriptionally regulated by the hypoxia inducible factors (HIF-1alpha/HIF-2alpha), which are tightly controlled by the HIF-prolyl hydroxylases (PHD). Hypoxia induces expression of the PHD2 and PHD3 proteins in tumors but the pathobiological significance of these events is uncertain. Here, we show that PHD2 and PHD3 induction acts within a negative feedback loop to limit the hypoxic HIF response. In glioblastomas, PHD2 and PHD3 are hypoxia-inducible in vitro and expressed in hypoxic areas of tumors in vivo. Comparison with other PHDs revealed distinct cytoplasmatic and nuclear localization patterns of PHD2 and PHD3. Gain and loss of function experiments defined PHD2 and PHD3 as HIF target genes that remained operative even at low oxygen concentrations. We found that increased PHD levels could compensate for reduced oxygen availability to regulate the HIF response. This negative feedback loop protected tumor cells against hypoxia-induced cell death, functionally implicating this pathway in the control of the tumor-suppressive components of the HIF system in glioblastoma. Moreover, PHD inhibition facilitated cell death induction by staurosporine or tumor necrosis factor-related apoptosis-inducing ligand, hinting at a more general protective role of PHD in the regulation of cell viability. In summary, our findings recognize the PHD/HIF regulatory axis as a novel therapeutic target to disable a tumor's ability to adjust to hypoxic conditions and control cell survival, helping to potentially overcome therapeutic cell death resistance in glioblastomas.

[1]  J. Fandrey,et al.  Nuclear Oxygen Sensing: Induction of Endogenous Prolyl-hydroxylase 2 Activity by Hypoxia and Nitric Oxide* , 2008, Journal of Biological Chemistry.

[2]  P. Bedossa,et al.  Overexpression of the Oxygen Sensors PHD-1, PHD-2, PHD-3, and FIH Is Associated with Tumor Aggressiveness in Pancreatic Endocrine Tumors , 2008, Clinical Cancer Research.

[3]  S. Fulda,et al.  Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. , 2008, Cancer research.

[4]  M. Meyerson,et al.  The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. , 2008, Genes & development.

[5]  J. Pouysségur,et al.  PHDs overactivation during chronic hypoxia “desensitizes” HIFα and protects cells from necrosis , 2008, Proceedings of the National Academy of Sciences.

[6]  T. Mak,et al.  FOXO3a is activated in response to hypoxic stress and inhibits HIF1-induced apoptosis via regulation of CITED2. , 2007, Molecular cell.

[7]  W. Halliday,et al.  Upregulation of Hypoxia-Inducible Factor (HIF)-1&agr; and HIF-2&agr; in Leptomeningeal Vascular Malformations of Sturge-Weber Syndrome , 2007, Journal of neuropathology and experimental neurology.

[8]  Roland H Wenger,et al.  Increased Prolyl 4-Hydroxylase Domain Proteins Compensate for Decreased Oxygen Levels , 2006, Journal of Biological Chemistry.

[9]  J. Pouysségur,et al.  Hypoxia signalling in cancer and approaches to enforce tumour regression , 2006, Nature.

[10]  P. Kronqvist,et al.  Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  L. del Peso,et al.  Identification of a functional hypoxia-responsive element that regulates the expression of the egl nine homologue 3 (egln3/phd3) gene. , 2005, The Biochemical journal.

[12]  P. Carmeliet,et al.  Genetic evidence for a tumor suppressor role of HIF-2alpha. , 2005, Cancer cell.

[13]  W. Kaelin,et al.  Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. , 2005, Cancer cell.

[14]  W. Jelkmann,et al.  Regulation of the prolyl hydroxylase domain protein 2 (phd2/egln-1) gene: identification of a functional hypoxia-responsive element. , 2005, The Biochemical journal.

[15]  Patrick D. Sutphin,et al.  Coordinate Regulation of the Oxygen-Dependent Degradation Domains of Hypoxia-Inducible Factor 1α , 2005, Molecular and Cellular Biology.

[16]  P. Ratcliffe,et al.  Determination and comparison of specific activity of the HIF‐prolyl hydroxylases , 2004, FEBS letters.

[17]  A. Harris,et al.  Differential Function of the Prolyl Hydroxylases PHD1, PHD2, and PHD3 in the Regulation of Hypoxia-inducible Factor* , 2004, Journal of Biological Chemistry.

[18]  Till Acker,et al.  Cellular oxygen sensing need in CNS function: physiological and pathological implications , 2004, Journal of Experimental Biology.

[19]  P. Jaakkola,et al.  Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases. , 2004, The Biochemical journal.

[20]  M. Wood,et al.  Regulation of HIF prolyl hydroxylases by hypoxia‐inducible factors , 2004, Journal of cellular biochemistry.

[21]  Varda Rotter,et al.  Expression of prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1alpha activation and inhibits tumor growth. , 2003, Cancer research.

[22]  Christian Frelin,et al.  Hypoxia Up-regulates Prolyl Hydroxylase Activity , 2003, Journal of Biological Chemistry.

[23]  G. Semenza Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[24]  J. Pouysségur,et al.  HIF prolyl‐hydroxylase 2 is the key oxygen sensor setting low steady‐state levels of HIF‐1α in normoxia , 2003, The EMBO journal.

[25]  K. Kivirikko,et al.  Characterization of the Human Prolyl 4-Hydroxylases That Modify the Hypoxia-inducible Factor* , 2003, Journal of Biological Chemistry.

[26]  Matthias Schramm,et al.  Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxia-inducible transcription factors. , 2002, Biochemical and biophysical research communications.

[27]  K. Polyak,et al.  Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression) , 2002, Oncogene.

[28]  S. McKnight,et al.  A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF , 2001, Science.

[29]  Michael I. Wilson,et al.  C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation , 2001, Cell.

[30]  R. Freeman,et al.  SM-20 Is a Novel Mitochondrial Protein That Causes Caspase-dependent Cell Death in Nerve Growth Factor-dependent Neurons* , 2001, The Journal of Biological Chemistry.

[31]  A. Harris,et al.  Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. , 2000, Cancer research.

[32]  Andrew L. Kung,et al.  Suppression of tumor growth through disruption of hypoxia-inducible transcription , 2000, Nature Medicine.

[33]  Inga Hallin,et al.  Modulation of phenotype and induction of irregular vessels accompany high tumorigenic potential of clonal human glioma cells xenografted to nude‐rat brain , 2000, International journal of cancer.

[34]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[35]  C. Thrash-Bingham,et al.  aHIF: a natural antisense transcript overexpressed in human renal cancer and during hypoxia. , 1999, Journal of the National Cancer Institute.

[36]  P. Carmeliet,et al.  Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.

[37]  Jessica Lo,et al.  HIF‐1α is required for solid tumor formation and embryonic vascularization , 1998 .

[38]  A. Giaccia,et al.  The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. , 1998, Cancer research.

[39]  D. Hanahan,et al.  Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. , 1997, Cancer research.

[40]  S. Madden,et al.  Induction of cell growth regulatory genes by p53. , 1996, Cancer research.

[41]  M. Taubman,et al.  Identification of a novel growth factor-responsive gene in vascular smooth muscle cells. , 1994, The Journal of biological chemistry.

[42]  P. Ratcliffe,et al.  Studies on the activity of the hypoxia-inducible-factor hydroxylases using an oxygen consumption assay. , 2007, The Biochemical journal.

[43]  W. Hamel,et al.  Karyotype analyses of 20 human glioma cell lines , 2005, Acta Neurochirurgica.

[44]  M. Taubman,et al.  Mammalian EGLN genes have distinct patterns of mRNA expression and regulation. , 2002, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[45]  S. Bhattacharya,et al.  Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. , 1999, Genes & development.